false
0001412486
0001412486
2025-08-05
2025-08-05
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 5, 2025
Cocrystal Pharma, Inc.
(Exact name of registrant as specified in its charter)
| Delaware |
|
001-38418 |
|
35-2528215 |
|
(State or other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
|
19805 N. Creek Parkway
Bothell, WA |
|
98011 |
| (Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: (877) 262-7123
(Former name or former address, if changed since
last report.): n/a
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b)
of the Act:
| Title of Each Class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
| Common Stock |
|
COCP |
|
The Nasdaq Stock Market LLC
(The Nasdaq Capital Market) |
Item 7.01 Regulation FD Disclosure.
On August
5, 2025, Cocrystal Pharma, Inc. (the “Company”) issued a press release announcing the presentation of safety and tolerability
data from a randomized, double-blinded, placebo-controlled Phase 1 study with its oral, direct-acting pan-viral inhibitor CDI-988 at the
2025 Military Health System Research Symposium (MHSRS), being held August 4-7, 2025 in Kissimmee, Florida. A copy of the press release
is being furnished as Exhibit 99.1, and a copy of the slide presentation is being furnished as Exhibit 99.2.
The information
in this Item 7.01 (including Exhibits 99.1 and 99.2) shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities under such section, and shall not be deemed
to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Exchange Act.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
| Exhibit |
|
Description |
| |
|
|
| 99.1 |
|
Press Release dated August 5, 2025 |
| 99.2 |
|
Presentation dated August 5, 2025 |
| 104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
Cocrystal Pharma, Inc. |
| |
|
|
| Date: August 5, 2025 |
By: |
/s/ James Martin |
| |
Name: |
James Martin |
| |
Title: |
Chief Financial Officer and Co-Chief Executive Officer |
| |
|
|
